

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS PO Box 1450 Alexasofan, Virginia 22313-1450 www.repto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/606,879	06/27/2003	Lieven Stuyver	BJS-2551-123	5237	
23117 NIXON & VA	7590 12/18/200 NDERHYE, PC	EXAM	EXAMINER		
901 NORTH C	ELEBE ROAD, 11TH F	PENG, BO			
ARLINGTON	, VA 22203		ART UNIT	PAPER NUMBER	
			1648		
			MAIL DATE	DELIVERY MODE	
			12/18/2009	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Ī	Application No.	Applicant(s)	_	
	10/606,879	STUYVER ET AL.		
	Examiner	Art Unit	_	
	BO PENG	1648		

	BO PENG	1648							
The MAILING DATE of this communication appe	ears on the cover sheet with the	correspondence add	ress						
THE REPLY FILED 08 December 2009 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.									
In REPLATION OF DESCRIPTION OF ALLOWANCE. IN STREET OF THE OFFICE OFFICE OF THE OFFICE OFFIC									
 a) The period for reply expiresmonths from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whicheve no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED V 									
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).								
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filled is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set fort in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filled, may reduce any serined patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL									
2. QThe Notice of Appeal was filed on <u>08 December 2009</u> . A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in CFR 41.37(a).									
<u>AMENDMENTS</u>									
 ∑ The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) ∑ They raise new issues that would require further consideration and/or search (see NOTE below); (b) ∑ They raise the issue of new matter (see NOTE below); 									
(c) ☐ They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or									
(d) They present additional claims without canceling a		ected claims.							
NOTE: See Continuation Sheet. (See 37 CFR 1.1									
4. The amendments are not in compliance with 37 CFR 1.1.		mpliant Amendment (PTOL-324).						
 Applicant's reply has overcome the following rejection(s) Newly proposed or amended claim(s) would be all 		timely filed amendmen	nt canceling the						
non-allowable claim(s).	iowabie ii subiliitteu iii a separate, i	unitery filed afficiation	it canceling the						
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro- The status of the claim(s) is (or will be) as follows:		I be entered and an e	xplanation of						
Claim(s) allowed:									
Claim(s) objected to: 35,36 and 38.									
Claim(s) rejected: 16,28,29 and 35-40. Claim(s) withdrawn from consideration: 18-27,31,32 and	34								
AFFIDAVIT OR OTHER EVIDENCE									
 The affidavit or other evidence filed after a final action, bu because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 									
9. The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).									
10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER									
11. Some requiremental than the requirement of the									
12. ☐ Note the attached Information <i>Disclosure Statement</i> (s). (PTO/SB/08) Paper No(s) 13. ☐ Other:									
(PO DENC)									
	/BO PENG/ Primary Examiner, Art U	Init 1648							

U.S. Patent and Trademark Office PTOL-303 (Rev. 08-06)

Continuation of 3. NOTE: New limitations added to the claims 36 step (iv) raise new issue and require new search and further consideration.

Continuation of 11, does NOT place the application in condition for allowance because: Applicants' arguments are not sufficient to overcome all outstranding rejections:

In response to the rejection of Claims 16, 28, 29 and 35-40 under 35 U.S.C. 112, 1st, Applicants argue that the claims are supported by an adequate writine description and that one of ordinary skill will be able to make and use the claimed invention without undue experimentation. This argument is not sufficient to overcome the rejection. As indicated in the Final Office action, para 13, the scope of new Claim 36 encompasses use of any undefined nucleotide probes of about 5 to 50 nucleotides long to specifically detect "the presence or absence of HBV genotype A", but not other HBV genotype A", as sample. However, the newly cited primers SEG ID NOS: 75, 76, 94, 105, 112, 134 and 135 appear to overlap with HBV genomes of other genotypes see Specification, Fig. 1, incleding that the cited primers are not genotype-specific. Since the cited primers in Claim 36 cannot yield the required result of 'determining the presence or absence of HBV genotype A in a biological sample" cited in the preamble of Claim 36, one of ordinary skill in the art will NOT be able to make and use the claimed invention, without undex experimentation.

In response to the 103 rejection of Claimay, a6 and 39, Applicants argue that the four primers as indicated amplify the HBsAg region of many different genopyes in a very efficient way, and the use of these primers is an unexpected advantage of the claim dinvention. This argument is considered, but not persussive. This argument is not relevant to the claims. It is noted that "the four primers" are not required in the claimed method. See Para 19, the final office action, dated June 8, 2009.

If the amendment were entered, the objection to Claim 38 under 37 CFR 1.75, as being a substantial duplicate of claim 29, would be moot in view of the amendment to the claim. The objection to Claims 35 and 36 as indefinite would be withdrawn in view of the amendment to the claims.

If the amendment were entered, the rejection of Claims 16 and 35 under 35 U.S.C. 112, 1st would be withdrawn.